It's a high-risk trade, but this biotech down 80% this year could be a buy

Sarepta Therapeutics (SRPT) stock, down 81% year-to-date due to safety concerns surrounding its Duchenne muscular dystrophy drug Elevidys and pending FDA guidance, is now exhibiting technical indicators suggesting a potential reversal. Despite the high headline risk, the stock has found a bottom, broken its longer-term downtrend, and is trading above its 50-day moving average, with analysts identifying a potential 50% upside from current levels as it fills a previous gap. This high-risk, high-reward scenario is further influenced by upcoming earnings on November 3 and the critical FDA decision regarding the drug's safety guidelines.

Analysis

Sarepta Therapeutics (SRPT) has experienced a significant 81% year-to-date decline, primarily due to safety concerns surrounding its Duchenne muscular dystrophy drug, Elevidys, which led to a patient death and acute liver failure. The company is currently awaiting critical FDA guidance on final safety guidelines for its gene therapies, having already suspended shipments for non-ambulatory patients, representing a substantial headline risk. This contrasts with the broader biotech sector, where the SPDR S&P Biotech ETF (XBI) is up 25% year-to-date.

Despite these fundamental headwinds, SRPT is exhibiting several technical indicators suggesting a potential reversal, having found a bottom since its August low of $10.41 and consistently forming higher lows. The stock has broken its longer-term downtrend from March highs and has recaptured and sustained above its 50-day moving average since August, which is now acting as support.

This technical strength is allowing SRPT to rally and fill a previous downward gap, which could offer approximately 50% upside from current levels, with price targets identified at $34 and $43. Upcoming catalysts include the crucial FDA decision on Elevidys' safety guidelines and the Q3 earnings report on November 3, following a 10.5% gain after snapping a six-quarter losing streak last quarter.

While longer-term momentum indicators (RSI, MACD on 5-year weekly chart) are flashing buy signals, short-term indicators are not, underscoring the speculative nature of the potential turnaround. SRPT presents a high-risk, high-reward scenario, with a suggested downside stop under $20 to limit potential losses to just over 10% against a 50% upside potential.

Key Decisions for Investors

• Investors should recognize Sarepta (SRPT) as a high-risk, high-reward opportunity driven by technical reversal signals and significant regulatory uncertainty.
• Closely monitor the upcoming FDA decision regarding Elevidys' safety guidelines and the Q3 earnings report on November 3, as these are critical catalysts for future price action.
• Consider utilizing technical analysis for entry and exit points, such as the identified 50% upside potential from gap filling and setting downside stop-loss orders (e.g., below $20) to manage risk effectively.